News brief­ing: Boehringer In­gel­heim ex­pands pro­tein degra­da­tion ef­forts; Pfiz­er en­lists a new AI part­ner

Boehringer In­gel­heim is ex­pand­ing its ef­forts in pro­tein degra­da­tion, sign­ing a pact with the Aus­tri­an biotech Prox­y­gen to de­vel­op a tech­nol­o­gy known as “mol­e­c­u­lar glue de­graders.”

Sim­i­lar to the PRO­TACS that com­pa­nies have fo­cused on to date, mol­e­c­u­lar glue de­graders are de­signed to bridge pro­teins to the body’s own in­ter­nal dis­pos­al sys­tem, al­low­ing re­searchers to tar­get pro­teins that can’t be hit by tra­di­tion­al small mol­e­cules. The mul­ti­ple myelo­ma drugs Revlim­id and Po­m­a­lyst work in this man­ner. Found­ed in 2016, Prox­y­gen has worked to de­vel­op meth­ods of sys­tem­at­i­cal­ly find­ing new ones.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER